Regenerative medicine is entering a pivotal phase, shifting from long-standing scientific promise toward practical clinical application. BioRestorative Therapies, Inc. is at the forefront of this transition, advancing stem cell-based therapies for high-need conditions such as degenerative disc disease while building a complementary commercial platform in bio-cosmeceuticals. In this conversation with BioPharma Boardroom, CEO Lance Alstodt outlines how the company is overcoming key barriers in clinical translation, differentiating its lead candidate BRTX-100, and leveraging rigorous data, scalable manufacturing, and strategic diversification to bring regenerative medicine closer to routine care.

Q1. Regenerative medicine has long held promise but faced hurdles in clinical translation and commercialization. How is BioRestorative Therapies overcoming these barriers to bring stem cell-based therapies closer to routine clinical use?

We are focused on targeted indications, practical delivery, and real-world applicability. Rather than pursuing broad or exploratory use cases, BioRestorative Therapies is focused on well-defined conditions. We are advancing our BRTX-100 therapy in high-need conditions such as chronic lumbar disc disease, where there is a large population with a clear unmet need. This focus increases the likelihood of meaningful clinical adoption.

Additionally, our approach is designed for integration into existing clinical workflows. BRTX-100 uses an autologous (meaning we use a patient’s own cells), minimally invasive procedure that can be performed in an outpatient setting. This makes it more accessible and scalable compared to more complex cell therapy models.

Q2. BRTX-100 targets chronic lower back pain linked to degenerative disc disease—an area still largely managed surgically. What differentiates your approach, and what evidence suggests it could shift treatment paradigms?

BRTX-100, unlike the other options, does not simply treat the symptoms but resolves the root cause of the pain. A key benefit of the therapy is its potential to treat chronic lower back pain associated with degenerative disc disease without relying on surgery or on opioid-based pain management. BRTX-100 is a product formulated from autologous expanded mesenchymal stem cells harvested from the patient’s bone marrow. Using an autologous approach improves safety and reduces the risk of rejection. 

Another differentiator of our approach is the use of a hypoxic, or low-oxygen, expansion process during the manufacturing of BRTX-100. By cultivating cells in a low-oxygen environment that closely mimics the conditions found in the human body’s disc tissue, we enhance the therapeutic potential and viability of the stem cells. This method is designed to improve cell function and persistence after transplantation, offering a more physiologically relevant and potentially more effective treatment compared to traditional cell expansion under normal oxygen levels.

We believe that BRTX-100 could shift treatment paradigms because of its effectiveness and design to address the root cause of the disease rather than just treating symptoms. Surgery and other current options do not heal the source of the pain as our therapy does.

Q3. As regulatory scrutiny around cell therapies intensifies globally, how are you navigating evolving frameworks while maintaining development speed and scientific integrity?

BioRestorative Therapies has taken a proactive approach that prioritizes both speed and rigor. We have focused on early and continuous engagement with the FDA. For BRTX-100, BioRestorative Therapies has already achieved meaningful alignment through formal interactions, including a Type B meeting under Fast Track designation, where key elements of the Phase 3 program, including trial design, endpoints, dosing, and CMC, were confirmed with no safety concerns raised.

We are also committed to high-quality, evidence-driven clinical development. Our Phase 2 trial for BRTX-100 is one of the largest and most rigorously designed FDA-authorized studies in chronic lumbar disc disease, reflecting a broader industry shift toward robust datasets, validated endpoints, and well-controlled trials to meet heightened regulatory expectations. This disciplined approach helps de-risk later-stage development while preserving development timelines.

Additionally, we have built a strong Chemistry, Manufacturing, and Controls (CMC) foundation, which regulators increasingly view as important to approval. Our proprietary manufacturing processes and validated framework align with regulatory focus on consistency, comparability, and product quality in cell therapies.

Q4. Your business spans both therapeutic development and bio-cosmeceutical applications. How do these two platforms complement each other strategically, particularly in terms of revenue generation and innovation cycles?

The BioCosmeceuticals platform was an intentional extension of our core expertise in regenerative medicine. As we advanced our clinical programs, we recognized that many of the same biologic mechanisms, particularly around cell signaling, exosomes, and tissue repair, have powerful applications in aesthetics and wellness. Also, as a vertically-integrated company, BioRestorative Therapies is able to effectively manage the entire lifecycle of our commercial products.

BioCosmeceuticals complements our clinical programs, validates our technology, and helps drive both near- and long-term value through revenue generation.

Q5. The market for exosome- and secretome-based products is expanding rapidly but remains fragmented. What sets BioRestorative’s offerings apart in terms of scientific validation and clinical credibility?

BioRestorative Therapies is developing proprietary secretome-derived cosmetic and dermatologic products (exosomes, growth factors, cytokines) for professional aesthetics, medical-grade skincare, and at-home regenerative use. These biologic formulations are developed using proprietary methods in a cGMP ISO 7 certified facility, ensuring clinical-grade quality for aesthetic uses.

Q6. Looking ahead, what do you see as the biggest unlock for regenerative medicine—clinical data, manufacturing scalability, reimbursement pathways, or physician adoption—and how is BioRestorative positioning itself accordingly?

We believe that the biggest unlock for regenerative medicine is strong clinical data. It underpins everything else, from regulatory approval to reimbursement and physician adoption. BioRestorative Therapies is positioning itself accordingly by generating rigorous, high-quality clinical evidence, as seen with our large, well-controlled Phase 2 trial for BRTX-100 and clear alignment with the FDA on our Phase 3 pathway. This data-driven approach de-risks development and builds the foundation for clinical adoption.

At the same time, we also have scalable manufacturing capabilities and a validated CMC framework, ensuring that we can deliver consistently as demand grows.

We are leading with our focus on data, while building the infrastructure needed to translate that data into real-world adoption.